Literature DB >> 16932505

Technology Insight: imaging amyloid plaques in the living brain with positron emission tomography and MRI.

Dan E Huddleston1, Scott A Small.   

Abstract

Alois Alzheimer first imaged amyloid plaques in 1906 by examining dead tissue under the microscope, but their clinical significance has remained undetermined. Now, nearly a century later, investigators are beginning to image amyloid plaques in living brains using both positron emission tomography and MRI. In this article, we review the studies that report on these recent technical advances, and discuss their potential importance in clarifying the diagnostic and pathogenic relevance of amyloid plaques to Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16932505     DOI: 10.1038/ncpneuro0046

Source DB:  PubMed          Journal:  Nat Clin Pract Neurol        ISSN: 1745-834X


  5 in total

Review 1.  Promoter DNA hypermethylation - Implications for Alzheimer's disease.

Authors:  Yiyuan Liu; Minghui Wang; Edoardo M Marcora; Bin Zhang; Alison M Goate
Journal:  Neurosci Lett       Date:  2019-07-24       Impact factor: 3.046

Review 2.  Recent progress in the development of metal complexes as β-amyloid imaging probes in the brain.

Authors:  Kaihua Chen; Mengchao Cui
Journal:  Medchemcomm       Date:  2017-05-16       Impact factor: 3.597

3.  Detection of amyloid plaques targeted by USPIO-Aβ1-42 in Alzheimer's disease transgenic mice using magnetic resonance microimaging.

Authors:  Jing Yang; Youssef Zaim Wadghiri; Dung Minh Hoang; Wai Tsui; Yanjie Sun; Erika Chung; Yongsheng Li; Andrew Wang; Mony de Leon; Thomas Wisniewski
Journal:  Neuroimage       Date:  2011-01-19       Impact factor: 6.556

4.  A Metal-Free Method for Producing MRI Contrast at Amyloid-β.

Authors:  Silvia Hilt; Tang Tang; Jeffrey H Walton; Madhu Budamagunta; Izumi Maezawa; Tamás Kálai; Kálmán Hideg; Vikrant Singh; Heike Wulff; Qizhi Gong; Lee-Way Jin; Angelique Louie; John C Voss
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

5.  Development of an MRI contrast agent for both detection and inhibition of the amyloid-β fibrillation process.

Authors:  Rohmad Yudi Utomo; Satoshi Okada; Akira Sumiyoshi; Ichio Aoki; Hiroyuki Nakamura
Journal:  RSC Adv       Date:  2022-02-09       Impact factor: 3.361

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.